Roche· @Roche · X·· 2026-07-24精选AI 评分60
AI 导读
罗氏宣布CHMP已推荐批准其用于成人新生血管性年龄相关性黄斑变性（nAMD）的持续给药疗法。nAMD是60岁以上人群失明的主要原因。罗氏未在帖文中披露该疗法的具体名称与临床数据。
推荐理由
罗氏披露CHMP对其nAMD持续给药疗法给出积极意见，可了解该给药方式在欧洲的审评进展。
正文
#MEDIA – We are pleased to share that the CHMP has recommended approval of our continuous delivery treatment for adults with neovascular age-related macular degeneration (#nAMD) - the leading cause of blindness in people over 60. 👉 https://spkl.io/60127J2hs
来源：Roche · x.com